Het effect van electronisch gegenereerde feedback over reumageneesmiddelen bij patiënten met reumatoïde artritis

Effectiveness of electronic drug monitoring feedback in order to decrease medication non-adherence, (biological)medication costs and time with high disease activity in RA-patients treated with DMARDs

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON26997

Enrollment

168

Registered

2014-07-03

Start date

2014-07-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adherence, Electronic Monitoring, Rheumatoid Arthritis, Disease activity Therapietrouw Reumatoïde arthritis ziekteactiviteit

Interventions

Patients in the intervention group receive their medication during 1 year in an electronic device. Before each regular (3-monthly) consult to the rheumatologist, patients medication adherence will be

Eligibility

Inclusion criteria

Inclusion criteria: • newly diagnosed with RA (2010 ARA criteria or clinical judgement rheumatologist) • initiating DMARDS • >18 years • sufficient ability to understand Dutch • be able to be followed for 12 months (life expectancy)

Exclusion criteria

Exclusion criteria: • large cognitive limitations • assistance in taking drugs (e.g. home care) • included in another randomised controlled trial

Design outcomes

Primary

Measure	Time frame
The difference in proportion of non-adherence patients (less than 80% medication adherence) after 1 year	—

Secondary

Measure	Time frame
Time to low disease activity, time to the first anti-TNF, the proportion of patients on anti-TNF therapy and disease activity after 1 year	—

Contacts

Public ContactA. Houterman

Sint Maartenskliniek Hengstdal 3

a.houterman@maartenskliniek.nl024 327 2767

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)